Adicet Bio reported early clinical signals for prula-cel, an off-the-shelf CAR-T approach, in a lupus trial, with the company stating that a subset of patients achieved complete kidney responses and remission endpoints after about one year of follow-up. The results are from an early-stage study in lupus nephritis, where many patients have already failed multiple prior therapies. Adicet said it did not see serious cytokine release syndrome cases or neurological side effects in this dataset, addressing key safety concerns seen with some individualized CAR-T approaches. The company plans to initiate a pivotal study in lupus in the fourth quarter, with investors reacting to both efficacy signals and ongoing uncertainty.